长春瑞滨联合卡铂治疗老年晚期NSCLC 的临床研究

 目的 观察长春瑞滨联合卡铂治疗老年晚期非小细胞肺癌的临床疗效和毒副反应。方法 33例70岁以上的老年晚期非小细胞肺癌患者，用国产长春瑞滨（盖诺）联合卡铂（NC方案）治疗：盖诺25mg／m^2，静注d1，8，卡铂AUC=5-6静滴d1，21～28天为一周期，每个患者接受至少两个周期的化疗。结果 有效率（CR＋PR）为39．4％（13／33），生存质量改善率为75．8％（25／33），中位生存期为11月。中位缓解期为7．0月。主要毒副反应为骨髓抑制。结论 NC方案治疗老年晚期非小细胞肺癌有一定疗效，且毒副作用可耐受。

Combination of Navelbine and Carboplatin in the Elderly with Advanced Non-small Cell Lung Cancer

Objective 　To evaluate the efficacy and toxicity of the comination of navelbine and carboplatin in the elderly with advanced non-small cell lung cancer (NSCLC) . Methods 　Thirty three patient s with locally advanced ( stage ⅢB) or metastatic ( stage Ⅳ) NSCLC were enrolled into the study. The patients received navelbine 25mg/ m² on days 1 ,8 , and carboplatin AUC 5～6 on day 1 , with 21～28 days as a cycle. Each patient received at least two cycles. Results 　Of the 33 patient s , there was none cases got complete response , 13 cases got partial response , 12 had stable disease , 8 had progressive disease , with an overall response rate 39. 4 % (13/ 33) . The median survival duration was 11 months. There were 75. 8 % (25/ 33) patient s whose KPS score increased. The main toxicities were leukopenia (incidence of 42 % for grade Ⅲ+ Ⅳ) and trombocytopenia (incidence of 18. 2 % for grade Ⅲ+ Ⅳ) . Conclusion 　The combination of navelbine and caboplatin is a feasible well-tolerated and active scheme in the elderly of advanced NSCLC.